

## REMARKS

Claims 1, 3, 4, 6-9, 11, 12, 14-16, 18, 22-25, 27, 31, and 37-45 are pending in the present application. Claims 37-39 and 43-45 have been amended. Claims 27, 31, and 40-42 have been canceled without prejudice. No new matter has been added.

Applicant wishes to thank the examiner for indicating that claims 1, 3, 4, 7-9, 11, 12, 15, 16, 18, 22-25, and 37-39 are allowed.

### **Claim rejection under 35 U.S.C. §112, first paragraph (written description)**

Claims 27, 31, and 40-45 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly lacking adequate written description.


Claims 27, 31, and 40-42 have been canceled without prejudice to their presentation in a continuing patent application, rendering the rejection of them moot.

In order to advance prosecution, claims 43-45 have been amended to even more clearly describe Applicant's inventions. These claims have been amended to recite that the claimed methods are directed to "[a] method of treating a disease..." As noted by the examiner at page 3 of the Action, the specification provides adequate support to establish that the inventors were in possession of this subject matter at the time of filing. Withdrawal of the rejection is requested.

### **Claim rejection under 35 U.S.C. §112, second paragraph**

Claims 6, 14, 27, 31, and 40-45 stand rejected under 35 U.S.C. §112, second paragraph for alleged indefiniteness. Applicant traverses this rejection.

For claims 6 and 14, the Examiner questions whether Applicant intended to insert "tert-butoxycarbonyl" into claims 1 and 9. It is noted that claims 1 and 9 claim, *inter alia*, a compound where R<sub>1</sub> is, *inter alia*, a protective group, and the protective group can be



, which is tert-butoxycarbonyl. Thus, claims 1 and 9 do include tert-butoxycarbonyl. The examiner suggests that claims 6 and 14 should be canceled, but they

**DOCKET NO.:** DRXI-0144  
**Application No.:** 10/634,335  
**Office Action Dated:** November 30, 2006

**PATENT**

properly depend from claims 1 and 9, respectively, and further limit the claims from which they depend. Withdrawal of this rejection is requested.

Claims 43-45, as noted above, have been amended to recite methods of treating a disease. In addition, claims 43-45 have also been amended to correct a typographical error and recite alternative Markush terminology. Withdrawal of this rejection is requested.

**Examiner's comments/notes**

Claims 37-39 have been amended as suggested by the examiner. These amendments are presented for clarity purposes only and do not modify the scope of the claims.

**Conclusion**

Claims 1, 3, 4, 6-9, 11, 12, 14-16, 18, 22-25, 37-39, and 43-45 are in condition for allowance. An early Notice of Allowance is requested.

Date: February 1, 2007

/Angela Verrecchio/  
Registration No. 54,510

Woodcock Washburn LLP  
Cira Centre, 12th Floor  
2929 Arch Street  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439